louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02946411: Correlation of Hospital Stay Length With the Glucose Levels After Cardiac Surgery
Official title: Correlation of Hospital Stay Length With the Glucose Measured Continuously Levels After Cardiac Surgery
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Stress Hyperglycemia
Keywords: Hyperglycemia
Lead sponsor: Coordinación de Investigación en Salud, Mexico
Sponsor class: OTHER_GOV
First posted: 2016-10-27
Enrollment: 48
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with a programmed cardiac surgery

Brief summary: The study is designed to test if there is any correlation between the glucose levels in the postoperatory period and the length of hospital stay.

Detailed description: The stress hyperglycemia commonly observed in the postoperatory period, there have been several studies to assess if there is benefit of having a strict glucose control or not.

This study will assess if there is correlation between the glucose levels measured continuously with the length of the stay in the hospital.

Eligibility criteria: Inclusion Criteria:

* Physical status classification of the American Society of Anesthesiologists (ASA) II-IV
* Patients programmed for cardiac surgery
* Any body mass index

Exclusion Criteria:

* Pregnant women
* Chronic Kidney Disease (CKD) Stage 2 or higher

Primary outcomes:
measure: Glucose
timeFrame: 5 days
Secondary outcomes:
measure: Hospital stay
timeFrame: [Days] Within the first 20 days after surgery
Other outcomes:
Locations:
city: Ciudad de mexico
country: Mexico
facility: Hospital de cardiología
state: Cdmx
Study officials:
affiliation: Investigator
name: Ana Gallardo, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00940511: Effects of Coordinated Care for Disabled Medicaid Recipients
Official title: Effects of Coordinated Care for Disabled Medicaid Recipients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Conditions Faced by Medicaid Recipients With Disabilities
Keywords: All conditions faced by disabled Medicaid recipients
Lead sponsor: MDRC
Sponsor class: OTHER
Collaborators: name: Center for Health Care Strategies
name: Robert Wood Johnson Foundation
name: Colorado Department of Health Care Policy and Financing
name: Kaiser Permanente
First posted: 2009-07-16
Enrollment: 2618
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to improve the quality of care for individuals with multiple chronic conditions, health care systems have begun turning to coordinated care. Although coordinated care can refer to many different things, it usually includes activities such as assessing patients' needs, referring them to the right doctors, helping them make and keep appointments, and helping them comply with medical or dietary recommendations. To understand the effects of coordinated care for high-needs Medicaid recipients, MDRC is conducting a randomized trial of a pilot coordinated care program run by Kaiser Permanente for blind and disabled Medicaid recipients in the Denver area.


Eligibility criteria: Inclusion Criteria:

* Disabled, in fee-for-service Medicaid

Exclusion Criteria:

* Under age 18, over age 64

Primary outcomes:
measure: Health care use through Medicaid
timeFrame: Two years
Secondary outcomes:
measure: Primary and preventive care
timeFrame: Six months, two years
measure: Emergency department use
timeFrame: Six months, two years
measure: Hospital admissions
timeFrame: Six months, two years
Other outcomes:
Locations:
city: Jefferson County
country: United States
facility: Kaiser Permanente
state: Colorado
Study officials:
affiliation: MDRC
name: Charles Michalopoulos, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Michalopoulos C, Manno MS, Warren A, Somers J. Managing Health Care for Medicaid Recipients with Disabilities: Final Report on the Kaiser Permanente Colorado Coordinated Care Pilot Program. New York: MDRC
citation: Kim SE, Michalopoulos C, Kwong RM, Warren A, Manno MS. Telephone care management's effectiveness in coordinating care for Medicaid beneficiaries in managed care: a randomized controlled study. Health Serv Res. 2013 Oct;48(5):1730-49. doi: 10.1111/1475-6773.12060. Epub 2013 Apr 5.
Clinical trial NCT05876611: Clinical Application of a Self Stabilizing Atlantoaxial Fusion Cage
Official title: Clinical Application of a Self Stabilizing Atlantoaxial Fusion Cage: a Cohort Study
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Atlantoaxial Dislocation
Lead sponsor: Peking University Third Hospital
Sponsor class: OTHER
First posted: 2023-05-25
Enrollment: 400
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with atlantoaxial dislocation

Brief summary: Conventional open surgery often requires extensive dissection of the muscle insertion points of the suboccipital muscle group during the insertion position and direction of the atlas axis screw, resulting in sustained postoperative occipital neck pain and movement dysfunction. In order to overcome the shortcomings of the prior art mentioned above, the present invention provides a self stabilizing fusion cage with a wing plate. During surgery, a thinner and smaller screw through the wing plate is used to achieve a secure connection between the atlas axis and the fusion cage. Due to the smaller screw size, the screw placement has higher safety. The purpose of this study is to compare the advantages of using this new fusion cage compared to traditional surgical instruments.


Eligibility criteria: Inclusion Criteria:

1. Atlantoaxial dislocation
2. Agree to use a new self stabilizing atlantoaxial fusion cage for surgery where feasible
3. Sign an informed consent form;

Exclusion Criteria:

1. Atlantoaxial dislocation without surgical treatment
2. Patients who refuse to participate in this project

Primary outcomes:
measure: fusion rate
timeFrame: 12 month follow up
measure: neural functions
timeFrame: 12 month follow up
measure: complications
timeFrame: 12 month follow up
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04986111: The Efficacy of Purse-string Skin Closure With Negative Pressure Wound Therapy (NPWT) After Ileostomy Reversal
Official title: The Efficacy of Purse-string Skin Closure With Negative Pressure Wound Therapy (NPWT) on Wound Recovery After Ileostomy Reversal: A Prospective Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Surgical Site Infection
Wound Heal
Lead sponsor: Seoul National University Bundang Hospital
Sponsor class: OTHER
First posted: 2021-08-02
Enrollment: 138
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Evaluating the effectiveness of the existing 'linear suture + wound drain placement' and 'purse-string suture + negative pressure wound therapy' through a prospective comparative study


Eligibility criteria: Inclusion Criteria:

* Patients experiencing ileostomy repair at multicenter

Exclusion Criteria:

* Active bacterial infection needing antibiotics before surgery
* parastomal infection before surgery
* uncontrolled diabetes mellitus
* Emergency repair of stoma (ex. stoma prolapse, high output stoma etc...)
* Inflammatory bowel disease

Primary outcomes:
measure: Unsuccessful wound recovery rate
timeFrame: Check at postoperative 30th day and report through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Seongnam-si
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
state: Gyeonggi-do
Study officials:
affiliation: Seoul National University Bundang Hospital
name: Duck-Woo Kim, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04980911: Iron Deficiency and Anemia in Cardiac Surgery
Official title: Iron Deficiency and Anemia in Cardiovascular Surgery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Anemia
Cardiac Surgery
Lead sponsor: Centre Hospitalier Régional Metz-Thionville
Sponsor class: OTHER
First posted: 2021-07-28
Enrollment: 1711
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient with iron deficiency and with a scheduled cardiac surgery

Brief summary: Anemia and preoperative iron deficit in cardiac surgery are associated by an increased volume of transfusion and an increase in complications and/or mortality. Recent studies have shown that EPO and iron administration the days preceding the operation results in a reduction of perioperative transfusion for patients with preoperative anemia.


Eligibility criteria: Inclusion Criteria:

* Patient with cardiac surgery
* With iron deficiency with or without anemia

Exclusion Criteria:

* Anemia without iron deficiency
* Iron overload
* Jehovah's witnesses
* Endocarditis
* Treating neoplasia
* Uncontrolled hypertension
* With infection
* Alfa-epoetin hypersensitivity
* Hypersensitivity of hamster's protein
* Erythroblastopenia induced by erythropoietin
* Ferinject or mannitol allergy

Primary outcomes:
measure: Number of transfusion
timeFrame: Day 7
Secondary outcomes:
measure: Number of post operative complications
timeFrame: Day 7
measure: Percentage of death
timeFrame: Day 7
Other outcomes:
Locations:
city: Metz
country: France
facility: CHR Metz Thionville
state: Moselle
Study officials:
References:
Clinical trial NCT02241811: Wound Treatment With 3% Sodium Pentaborate Pentahydrate
Official title: Deep Diabetic Foot Wound Treatment With Hydrogel Including 3% Sodium Pentaborate Pentahydrate
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Wound Healing
Keywords: Diabetic
Foot
Wound
Sodium pentaborate pentahydrate
Hydrogel
Lead sponsor: SB Istanbul Education and Research Hospital
Sponsor class: OTHER
Collaborators: name: Bezmialem Vakif University
First posted: 2014-09-16
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Chronic foot wounds which is very difficult to treat are common especially in diabetic and peripheral arterial or venous insufficiency patients. This research is aim to observe the foot wound's recovery with 3% Sodium pentaborate pentahydrate hydrogel.

Detailed description: Chronic foot wounds which is very difficult to treat are common especially in diabetic and peripheral arterial or venous insufficiency patients. For these reason we prepared a hydrogel formulations.

Gel preparation:

Hydrogel formulations were prepared by dispersing 1%(w/v) carbopol polymer (Carbopol Ultrez-21, Lubrizol, USA) in distilled water. Neutralization buffer (1.6g of 1M sodium hydroxide solution for 1L polymer-water suspension) was used for the gelation of the polymer. Sodium pentaborate pentahydrate (3% w/v), F68 (2% w/v) and F127 (2% w/v) were mixed into the blank hydrogel and stored at 4 °C until it completely dissolved (approximately 24 h). pH of the hydrogel formulation was set to 6.5-7.0 using 1M sodium hydroxide. The hydrogel without any active ingredient was used as negative control (vehicle).

For the first group after wound dressing we applied hydrogel with 3% Sodium pentaborate pentahydrate, and for the control group after wound dressing we applied hydrogel without any active ingredient everyday for two months. The same doctor observed and took photo of the wounds every week in the outpatients clinic.

Eligibility criteria: Inclusion Criteria:

Diabetic Foot wounds

Exclusion Criteria:

Child

Primary outcomes:
measure: Wound healing, Complication
timeFrame: 2 months
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Bezmialem Vakif University
Study officials:
affiliation: Bezmialem Vakif University
name: Erhan Aysan, MD Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06748911: Navicam for Detection of Barrett's Esophagus
Official title: Use of a Detachable String Capsule for Evaluation of Barrett's Esophagus
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Barrett's Esophagus
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2024-12-27
Enrollment: 57
Sex: ALL
Minimum age (years): 22
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: Using a non-invasive capsule system to achieve optimal viewing angles of the esophagus for detection of Barrett's esophagus


Eligibility criteria: Inclusion Criteria

* Adults greater than or equal to 22 years of age with or without Barrett's Esophagus
* All Patients:

  o Have had an endoscopy within 1 year of baseline enrollment
* Patients with Barrett's Esophagus:

  * Presence of at least 1cm of salmon colored mucosa with corresponding biopsies showing intestinal metaplasia who are treatment naïve and undergoing surveillance Or
  * Chronic Gastro Esophageal Reflux Disease (GERD) patients with at least 3 additional risk factors that meet Barrett's Esophagus screening criteria per latest clinical guidelines

Exclusion Criteria

* Inability to comprehend or read the consent form
* Have an oropharynx, esophageal, or gastro-esophageal tumor
* Ongoing symptoms of dysphagia
* Presence of active clinically significant stricture
* History of stricture requiring dilation
* Presence of pacemaker or implanted cardiac defibrillator
* History of esophageal surgery with the exception of fundoplication
* Pregnancy
* History of surgery or obstructive process of the small bowel
* BMI \> 38

Primary outcomes:
measure: Detection of Columnar lined epithelium in the esophagus
timeFrame: From start of procedure to removal of capsule, assessed up to 30 minutes timeframe from start to end of procedure..
Secondary outcomes:
measure: Visual Analogue Scale (VAS)
timeFrame: 30 minutes post-procedure
measure: Spielberger State-Trait Anxiety Inventory (STAI-6)
timeFrame: Baseline, 30 minutes post-procedure
measure: Impact of Events Scale (IES)
timeFrame: Baseline, 7 days post-procedure
Other outcomes:
Locations:
city: Jacksonville
country: United States
facility: Mayo Clinic in Florida
state: Florida
Study officials:
affiliation: Mayo Clinic
name: Swathi Eluri
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00856011: Nerve Morphology in Diabetic Patients
Official title: Posterior Interosseous Nerve Pathology May Provide Novel Insights Into Both Predisposition and Potential Vascular Basis for the Development of Carpal Tunnel Syndrome in Diabetic Patients.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Peripheral Neuropathy
Carpal Tunnel Syndrome
Entrapment Neuropathies
Diabetes Complications
Lead sponsor: Skane University Hospital
Sponsor class: OTHER
First posted: 2009-03-05
Enrollment: 46
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients referred to a specialized hand clinic

Brief summary: The underlying basis of carpal tunnel syndrome and the basis of its increased incidence in diabetes are unknown. The aim of this study was to quantified pathology in an uncompressed nerve (posterior interosseous nerve in the forearm between diabetic and non-diabetic patients with CTS.


Eligibility criteria: Inclusion Criteria

* Diagnosis of carpal tunnel syndrome based in clinical history and symptoms
* Confirmed by nerve conduction studies

Exclusion Criteria

* Other focal nerve entrapments
* Cervical radiculopathy
* Inflammatory joint disease
* Renal failure
* Thyroid disorders
* Previous wrist fracture
* Long-term exposure to vibrating tools
* Age under 18

Primary outcomes:
measure: Nerve morphology (Fascicular area, myelinated nerve fiber density, endoneurial capillary density and subperineurial space
Secondary outcomes:
Other outcomes:
Locations:
city: Malmo
country: Sweden
facility: Dept. of Hand Surgery, Malmo University Hospital
Study officials:
References:
Clinical trial NCT00120211: Trial of Five Versus Six Fractions Per Week for Head and Neck Cancer
Official title: Phase III Trial of Five Versus Six Fractions Per Week for Head and Neck Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Head and Neck Cancer
Lead sponsor: International Atomic Energy Agency
Sponsor class: OTHER_GOV
First posted: 2005-07-15
Enrollment: 855
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This trial compares the use of 6 fractions versus the standard 5 fractions of radiotherapy used in the treatment of head and neck cancer.

Detailed description: The purpose of this trial is to study the clinical effects of increasing the weekly fraction number for locally advanced head and neck cancers by a multi-institutional prospective randomised trial. The primary endpoint is to clarify whether a six fraction per week protocol has a greater effect on the survival, as compared to the conventional five fraction per week protocol.

Eligibility criteria: Inclusion Criteria:

* Head and Neck Cancer

Exclusion Criteria:

* Unable to give an informed consent

Primary outcomes:
measure: Three Years Loco-regional Control
timeFrame: 3 years
Secondary outcomes:
measure: Disease-specific Survival
timeFrame: 8 years
measure: Overall Survival
timeFrame: 8 years
measure: Acute Adverse Effects
measure: Late Adverse Effects
timeFrame: 8 years
Other outcomes:
Locations:
Study officials:
affiliation: International Atomic Energy Agency (IAEA)
name: Eduardo Rosenblatt, M.D.
role: STUDY_DIRECTOR
References:
citation: Overgaard J, Mohanti BK, Begum N, Ali R, Agarwal JP, Kuddu M, Bhasker S, Tatsuzaki H, Grau C. Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial. Lancet Oncol. 2010 Jun;11(6):553-60. doi: 10.1016/S1470-2045(10)70072-3. Epub 2010 Apr 8.
Clinical trial NCT00002211: Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients
Official title: An Open-Label Randomized Study of Delavirdine Mesylate (DLV, Rescriptor) Plus Nelfinavir (NFV), Didanosine (ddI), and Stavudine (d4T) in Triple and Quadruple Treatment Regimens in HIV-1 Infected Individuals
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: HIV Infections
Keywords: HIV-1
Didanosine
Stavudine
HIV Protease Inhibitors
RNA, Viral
Delavirdine
Reverse Transcriptase Inhibitors
Viral Load
Nelfinavir
Lead sponsor: NIH AIDS Clinical Trials Information Service
Sponsor class: INDUSTRY
First posted: 2001-08-31
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to see if it is safe and effective to give combinations of three or four anti-HIV drugs to HIV-infected patients. The drugs used in this study are delavirdine (DLV), nelfinavir (NLF), didanosine (ddI), and stavudine (d4T).

Detailed description: This is a multicenter, open-label study. Patients are stratified by HIV-1 RNA levels (20,000 to 200,000 copies/ml and greater than 200,000 copies/ml). Patients are equally randomized to one of four groups and receive antiretroviral therapy for 24 weeks. Group 1 receives delavirdine (DLV) plus nelfinavir (NFV) plus stavudine (d4T). Group 2 receives DLV plus NFV plus didanosine (ddI). Group 3 receives NFV plus d4T plus ddI. Group 4 receives DLV plus NFV plus d4T plus ddI. Patients are evaluated for drug safety and viral burden. Patients may opt to continue on the study for 24 additional weeks, at the discretion of the investigator.

Eligibility criteria: Inclusion Criteria

You may be eligible for this study if you:

* Are at least 18 years old.
* Are HIV-positive.
* Have a CD4 count of at least 50 cells/mm3.
* Have a viral load of at least 20,000 copies/ml.

Exclusion Criteria

You will not be eligible for this study if you:

* Have taken d4T.
* Have taken protease inhibitors, including NFV.
* Have taken nonnucleoside reverse transcriptase inhibitors.
* Have taken ddI for 1 month or more.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Peapack
country: United States
facility: Pharmacia & Upjohn
state: New Jersey
Study officials:
References: